Scalper1 News
Big pharma Bristol-Myers Squibb’s (BMY) cancer drug Opdivo continued to shine Friday, as the company halted another clinical trial early because it had already hit its endpoint. The phase-three trial, called Checkpoint-057, compared Opdivo in advanced non-squamous non-small-cell lung cancer with standard treatment docetaxel (better known as Sanofi’s (SNY) Taxotere). The study found a significant improvement in overall survival in the Opdivo arm, Scalper1 News
Scalper1 News